Gupta R, Woo K, Yi JA. Epidemiology of end-stage kidney disease. Semin Vasc Surg. 2021;34:71–78. https://doi.org/10.1053/j.semvascsurg.2021.02.010
Pilch NA, Bowman LJ, Taber DJ. Immunosuppression trends in solid organ transplantation: the future of individualization, monitoring, and management. Pharmacotherapy. 2021;41:119–31. https://doi.org/10.1002/phar.2481
Andrews LM, Li Y, De Winter BCM, Shi YY, Baan CC, Van Gelder T, et al. Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients. Expert Opin Drug Metab Toxicol. 2017;13:1225–36. https://doi.org/10.1080/17425255.2017.1395413
Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43:623–53. https://doi.org/10.2165/00003088-200443100-00001
O’Seaghdha CM, McQuillan R, Moran AM, Lavin P, Dorman A, O’Kelly P, et al. Higher tacrolimus trough levels on days 2–5 post-renal transplant are associated with reduced rates of acute rejection. Clin Transplant. 2009;23:462–68. https://doi.org/10.1111/j.1399-0012.2009.01021.x
Staatz C, Taylor P, Tett S. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant. 2001;16:1905–09. https://doi.org/10.1093/ndt/16.9.1905
Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs. 2003;63:1247–97. https://doi.org/10.2165/00003495-200363120-00006
Barraclough KA, Isbel NM, Kirkpatrick CM, Lee KJ, Taylor PJ, Johnson DW, et al. Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients. Br J Clin Pharmacol. 2011;71:207–23. https://doi.org/10.1111/j.1365-2125.2010.03815.x
Kim IW, Moon YJ, Ji E, Kim KI, Han N, Kim SJ, et al. Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients. Eur J Clin Pharmacol. 2012;68:657–69. https://doi.org/10.1007/s00228-011-1182-5
Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet. 2001;40:159–68. https://doi.org/10.2165/00003088-200140030-00002
Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet. 2010;49:141–75. https://doi.org/10.2165/11317350-000000000-00000
Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383–91. https://doi.org/10.1038/86882
Hesselink DA, Bouamar R, Elens L, van Schaik RH, van Gelder T. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2014;53:123–39. https://doi.org/10.1007/s40262-013-0120-3
Cheng Y, Li H, Meng Y, Liu H, Yang L, Xu T, et al. Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre. Int J Clin Pract Suppl 2015: 16-22. https://doi.org/10.1111/ijcp.12662.
MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant. 2004;4:914–9. https://doi.org/10.1111/j.1600-6143.2004.00435.x
Schirmer M, Rosenberger A, Klein K, Kulle B, Toliat MR, Nurnberg P, et al. Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics. 2007;8:443–53. https://doi.org/10.2217/14622416.8.5.443
Li CJ, Li L, Lin L, Jiang HX, Zhong ZY, Li WM, et al. Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients. Plos One. 2014;9:e86206 https://doi.org/10.1371/journal.pone.0086206
Liu MZ, He HY, Zhang YL, Hu YF, He FZ, Luo JQ, et al. IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients. Acta Pharmacol Sin. 2017;38:415–23. https://doi.org/10.1038/aps.2016.153
Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315:525–8. https://doi.org/10.1126/science.1135308
Akbas SH, Bilgen T, Keser I, Tuncer M, Yucetin L, Tosun O, et al. The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients. Transplant Proc. 2006;38:1290–2. https://doi.org/10.1016/j.transproceed.2006.02.079
Singh R, Srivastava A, Kapoor R, Mittal RD. Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period? J Clin Pharmacol. 2011;51:603–15. https://doi.org/10.1177/0091270010370704
Bonhomme-Faivre L, Picard V, Saliba F, Abbara C, Fodil M, Chaunoy M, et al. Effect of the ABCB1 3435C>T polymorphism on tacrolimus concentrations and dosage requirements in liver transplant recipients. Am J Health Syst Pharm. 2009;66:1645–51. https://doi.org/10.2146/ajhp080396
Panomvana D, Traiyawong T, Towanabut S. Effect of CYP3A5 genotypes on the pharmacokinetics of carbamazepine when used as monotherapy or Co-administered with phenytoin, phenobarbital or valproic acid in thai patients. J Pharm Pharm Sci. 2013;16:502–10. https://doi.org/10.18433/J3Q888
Veerakikosol K, Chariyavilaskul P, Townamchai N, Wittayalertpanya S. Association of CYP3A5 and POR polymorphisms with the maintenance tacrolimus dosage requirement in Thai recipients of kidney transplants. Asian Biomed. 2016;10:483–90. https://doi.org/10.5372/1905-7415.1005.512
Charoenchokthavee W, Panomvana D, Sriuranpong V, Areepium N. Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment. Breast Cancer (Dove Med Press). 2016;8:149–55. https://doi.org/10.2147/bctt.S105563
Yaowakulpatana K. Impact of CYP3A5 polymorphism on trough concentration to dose ratio of tacrolimus and early rejection in Thai renal transplant recipients [master’s thesis]. Bangkok, Thailand: Chulalongkorn University; 2014. https://doi.org/10.58837/CHULA.THE.2014.636
Areesinpitak T, Kanjanawart S, Nakkam N, Tassaneeyakul W, Vannaphasaht S. Prevalence of CYP2C19, CYP3A4 and FMO3 genetic polymorphisms in healthy northeastern Thai volunteers. ScienceAsia. 2020;46:397–402. https://doi.org/10.2306/scienceasia1513-1874.2020.050
Singkham N, Avihingsanon A, Bunupuradah T, Punyawudho B. Genotype and allele frequencies of ABCB1 and SLCO1B1 polymorphisms in THAI HIV-infected patients. Chula Med J. 2018;62:697–709. https://doi.org/10.58837/CHULA.CMJ.62.4.6
Sensorn I, Sirachainan E, Chamnanphon M, Pasomsub E, Trachu N, Supavilai P, et al. Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen. Pharmgenomics Pers Med. 2013;6:93–8. https://doi.org/10.2147/PGPM.S44006
Yaowakulpatana K, Vadcharavivad S, Ingsathit A, Areepium N, Kantachuvesiri S, Phakdeekitcharoen B, et al. Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation. Eur J Clin Pharmacol. 2016;72:277–83. https://doi.org/10.1007/s00228-015-1990-0
Shenoy MT, Manavalan J, AH, KS, Mohanty PK. Tacrolimus concentration/dose ratio: a tool for guiding tacrolimus dosage post-renal transplantation. Cureus. 2024;16:e53421 https://doi.org/10.7759/cureus.53421
Schütte-Nütgen K, Thölking G, Steinke J, Pavenstädt H, Schmidt R, Suwelack B, et al. Fast tac metabolizers at risk—it is time for a C/D ratio calculation. J Clin Med. 2019;8:587 https://doi.org/10.3390/jcm8050587
Wang J, Ji H, Jia H, Guan D. Association between CYP3A4 gene rs4646437 polymorphism and the risk of hypertension in Chinese population: a case-control study. Biosci Rep. 2019;39:BSR20190296 https://doi.org/10.1042/bsr20190296
Luo X, Zhu LJ, Cai NF, Zheng LY, Cheng ZN. Prediction of tacrolimus metabolism and dosage requirements based on CYP3A4 phenotype and CYP3A5(*)3 genotype in Chinese renal transplant recipients. Acta Pharmacol Sin. 2016;37:555–60. https://doi.org/10.1038/aps.2015.163
Xue Y, Zhao ZQ, Hong D, Zhang HJ, Chen HX, Fan SW. MDR1 gene polymorphisms are associated with glucocorticoid-induced avascular necrosis of the femoral head in a Chinese population. Genet Test Mol Biomarkers. 2014;18:196–201. https://doi.org/10.1089/gtmb.2013.0374
Solé X, Guinó E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006;22:1928–29. https://doi.org/10.1093/bioinformatics/btl268
Schutte-Nutgen K, Tholking G, Suwelack B, Reuter S. Tacrolimus – pharmacokinetic considerations for clinicians. Curr Drug Metab. 2018;19:342–50. https://doi.org/10.2174/1389200219666180101104159
Fan J, Wen P, Yuan L, Xia Y, Hu S, Zhang X, et al. Clinical significance and gene prediction of a novel classification system based on tacrolimus concentration-to-dose ratio in the early post-liver transplant period. Front Pharmacol. 2025;16:1614753 https://doi.org/10.3389/fphar.2025.1614753
Vidal-Alabró A, Colom H, Fontova P, Cerezo G, Melilli E, Montero N, et al. Tools for a personalized tacrolimus dose adjustment in the follow-up of renal transplant recipients. Metabolizing phenotype according to CYP3A genetic polymorphisms versus concentration-dose ratio. Nefrologia (Engl Ed). 2024;44:204–16. https://doi.org/10.1016/j.nefroe.2024.03.019
Sivakumar V, Rakshna M, Soorya MS, Pranesh S. Understanding the factors influencing pharmacokinetics of tacrolimus. Int J Res Med Sci. 2024;12:1769–75. https://doi.org/10.18203/2320-6012.ijrms20241273
Allegri L, Baldan F, Vallone C, Tulissi P, Gropuzzo M, Canelles MF, et al. Tacrolimus therapeutic drug monitoring in stable kidney transplantation and individuation of CYP3A5 genotype. Transplant Proc. 2019;51:2917–20. https://doi.org/10.1016/j.transproceed.2019.04.090
Khusnul K, Lolita, Lalu Muhammad I. The effect of CYP3A4, CYP3A5 and ABCB1 polymorphisms on tacrolimus dose requirements in adult kidney transplant patients. Prof Health J. 2026;8:166–78. https://doi.org/10.54832/phj.v8i1.1371
van Gelder T, Meziyerh S, Swen JJ, de Vries APJ, Moes D. The clinical impact of the C(0)/D ratio and the CYP3A5 genotype on outcome in tacrolimus treated kidney transplant recipients. Front Pharmacol. 2020;11:1142 https://doi.org/10.3389/fphar.2020.01142
Khan AR, Raza A, Firasat S, Abid A. CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis. Pharmacogenomics J. 2020;20:553–62. https://doi.org/10.1038/s41397-019-0144-7
Chinh D, Vu D, Le BH, Nguyen H, Nguyen T-L-H, Nguyen D. Both donor and recipient CYP3A5 gene polymorphisms represent as significant factors influencing Tacrolimus weight-dose adjusted concentration in the early phase after living donor liver transplantation. Pharm Sci Asia. 2025;51:1–10. https://doi.org/10.29090/psa.2025.01.24.AB0741
Uno T, Wada K, Matsuda S, Terada Y, Oita A, Kawase A, et al. Impact of the CYP3A5*1 allele on the pharmacokinetics of tacrolimus in japanese heart transplant patients. Eur J Drug Metab Pharmacokinet. 2018;43:665–73. https://doi.org/10.1007/s13318-018-0478-6
Cheng F, Li Q, Cui Z, Wang Z, Zeng F, Zhang Y. Tacrolimus concentration is effectively predicted using combined clinical and genetic factors in the perioperative period of kidney transplantation and associated with acute rejection. J Immunol Res. 2022;2022:3129389. https://doi.org/10.1155/2022/3129389
Yanik MV, Seifert ME, Locke JE, Hauptfeld-Dolejsek V, Crowley MR, Cutter GR, et al. CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients. Pediatr Transplant. 2019;23:e13494. https://doi.org/10.1111/petr.13494
Diamond A, Karhadkar S, Chavin K, Constantinescu S, Lau KN, Perez-Leal O, et al. Dosing strategies for de novo once-daily extended release tacrolimus in kidney transplant recipients based on CYP3A5 genotype. World J Transplant. 2023;13:368–78. https://doi.org/10.5500/wjt.v13.i6.368
Lim RW, Ho QY, Yeo YT, Liew IT, Tien CS-Y, Thangaraju S, et al. CYP3A5 genotyping-guided dosing versus weight-based dosing in a multi-ethnic population of kidney transplant recipients. Proc Singap Healthc. 2025;34:20101058251365300. https://doi.org/10.1177/20101058251365300
Singh R, Srivastava A, Kapoor R, Sharma KR, Mittal DR. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India. Naunyn Schmiedebergs Arch Pharmacol. 2009;380:169–77. https://doi.org/10.1007/s00210-009-0415-y
Ibrahim A. Genetic polymorphism in CYP3A4 and CYP3A5 genes and their association with the clinical response to calcineurin inhibitors; a narrative review. Precis Med Commun. 2024;4:21–40. https://doi.org/10.55627/pmc.004.001.0554
Mariño-Ramírez L, Sharma S, Hamilton JM, Nguyen TL, Gupta S, Natarajan AV, et al. The Consortium for Genomic Diversity, Ancestry, and Health in Colombia (CÓDIGO): building local capacity in genomics and bioinformatics. Commun Biol. 2025;8:1062. https://doi.org/10.1038/s42003-025-08496-9
Tang J, Xu J, Zhang YL, Liu R, Liu MZ, Hu YF, et al. Incorporation of gene-environment interaction terms improved the predictive accuracy of tacrolimus stable dose algorithms in chinese adult renal transplant recipients. J Clin Pharmacol. 2019;59:890–99. https://doi.org/10.1002/jcph.1379
Deininger KM, Vu A, Page IiRL, Ambardekar AV, Lindenfeld J, Aquilante CL. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients. Clin Transplant. 2016;30:1074–81. https://doi.org/10.1111/ctr.12790
Crettol S, Venetz JP, Fontana M, Aubert JD, Pascual M, Eap CB. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit. 2008;30:689–99. https://doi.org/10.1097/FTD.0b013e31818a2a60
Liu M, Hernandez S, Aquilante CL, Deininger KM, Lindenfeld J, Schlendorf KH, et al. Composite CYP3A (CYP3A4 and CYP3A5) phenotypes and influence on tacrolimus dose adjusted concentrations in adult heart transplant recipients. Pharmacogenomics J. 2024;24:4. https://doi.org/10.1038/s41397-024-00325-2
Li Z, Wang X, Li D, Cheng S, Dong Y, Yang H, et al. The impact of ABCB1 SNPs on tacrolimus pharmacokinetics in liver or kidney transplant recipients: a meta-analysis. Curr Pharm Des. 2023;29:2323–35. https://doi.org/10.2174/0113816128259239231009112019
Rong G, Jing L, Deng-Qing L, Hong-Shan Z, Shai-Hong Z, Xin-Min N. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in chinese renal transplant recipients. Transplant Proc. 2010;42:3455–8. https://doi.org/10.1016/j.transproceed.2010.08.063
da Costa-Junior LC, Freitas-Alves DR, Leão AML, Monteiro HdAV, de Cássia Barbosa da Silva Tavares R, Moreira MCR, et al. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 genes: implications for calcineurin inhibitors therapy in hematopoietic cell transplantation recipients—a systematic review. Front Pharmacol. 2025;16:1569353 https://doi.org/10.3389/fphar.2025.1569353
Shah F, Ali A, Bader Z, Hassan G. Pharmacogenetics of tacrolimus in solid organ transplant patients. Precis Med Commun. 2023;3:133–50. https://doi.org/10.55627/pmc.003.02.0387
Khamlek K, Komenkul V, Sriboonruang T, Wattanavijitkul T. Population pharmacokinetic models of tacrolimus in paediatric solid organ transplant recipients: a systematic review. Br J Clin Pharmacol. 2024;90:406–26. https://doi.org/10.1111/bcp.15909
Bahmany S, de Wit LEA, Hesselink DA, van Gelder T, Shuker NM, Baan C, et al. Highly sensitive and rapid determination of tacrolimus in peripheral blood mononuclear cells by liquid chromatography-tandem mass spectrometry. Biomed Chromatogr. 2019;33:e4416. https://doi.org/10.1002/bmc.4416